Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinal Vascular Disorders Clear all
Recruiting Phase 2 Interventional

Sleep, Diabetic Retinopathy and Melatonin

NCT04547439
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
Melatonin, Placebo
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 20, 2026, 10:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Adaptive Optics for Ophthalmic Technologies

NCT02826655
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
WF-AO-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

An Extension to Study MD7108240

NCT00733304
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 20, 2026, 10:15 PM EDT
Completed No phase listed Observational

Imaging Parameters and DME Treatment Response

NCT02637245
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
No intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 2 Interventional

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

NCT00344227
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Lucentis (Ranibizumab)
Drug
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2006 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Not applicable Interventional

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

NCT05491746
View directory record Official record
Conditions
Diabetic Retinopathy, Low Vision
Interventions
Eye4, Placebo
Device · Other
Lead sponsor
Eyedaptic
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 20, 2026, 10:15 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 20, 2026, 10:15 PM EDT
Active, not recruiting No phase listed Observational

Camera Qualification Study

NCT05808699
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
handheld fundus camera
Device
Lead sponsor
Digital Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Norco, California • Pomona, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 20, 2026, 10:15 PM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027
View directory record Official record
Conditions
Macular Edema, Cystoid, Retinal Vein Occlusion
Interventions
Standard Care, intravitreal triamcinolone injection
Other · Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 20, 2026, 10:15 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
View directory record Official record
Conditions
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
Combination Product
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

NCT01085734
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Avastin, Osurdex
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Not applicable Interventional

Circadian Amplification in Diabetic Retinopathy

NCT06183476
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Amplify-RHYTHM
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 20, 2026, 10:15 PM EDT
Terminated Phase 1 Interventional

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

NCT01334255
View directory record Official record
Conditions
Pigment Epithelial Detachment
Interventions
iSONEP (sonepcizumab/LT1009)
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 2 Interventional

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

NCT02387788
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
AKB-9778
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 20, 2026, 10:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 20, 2026, 10:15 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Retina is a Marker for Cerebrovascular Heath

NCT04753970
View directory record Official record
Conditions
Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease
Interventions
Cilostazol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Not applicable Interventional

Confronting Unequal Eye Care in Pennsylvania

NCT01179555
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus, Type 2, Glaucoma
Interventions
Behavioral Activation, Supportive Therapy
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 20, 2026, 10:15 PM EDT
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 20, 2026, 10:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

NCT03403686
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
blood draw
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 98 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 20, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT00320788
View directory record Official record
Conditions
Macular Degeneration
Interventions
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Sep 20, 2026, 10:15 PM EDT